System Value Evidence Reshapes Market Access Strategies

João L. Carapinha, Ph.D.

Healthcare decision-makers are increasingly turning to system value evidence when they assess new technologies. That shift has direct consequences for health economics, market access and the design of pricing strategies, which must hold under constrained budgets. Reflections from ISPOR Europe 2026 give leaders a view of how future submissions will be judged.

From product metrics to system outcomes

Traditional health technology assessment has concentrated on relative effectiveness, yet payers now require evidence that informs operational choices such as bed closures, admission avoidance and workforce reallocation. System value evidence answers these wider questions by linking clinical outcomes to population-level effects and capacity constraints. Cardiovascular, renal and metabolic conditions make the case: their rising share of research abstracts reflects the recognition that clustered diseases demand pathway-wide rather than product-specific analysis.

System value evidence that supports reimbursement decisions

Fit-for-purpose evidence succeeds when it reduces the residual uncertainties that shape reimbursement decisions. Continuous, co-created data generation after initial access allows payers to adjust arrangements based on longer follow-up or clearer benefit. In parallel, linked population datasets that connect clinical records with payment data give assessors a practical route to evaluate budget impact across entire health systems rather than isolated interventions.

Policy implications of global pricing pressures

Most-favoured-nation pricing arrangements originating in the United States have already altered European launch dynamics. Because a single European price effectively becomes a global reference, companies face difficult choices between delayed launches and lower returns. System value evidence matters most here, as it quantifies the trade-offs between headline price, expenditure predictability and the risk that new medicines bypass major markets.

Recommendations for HEOR and market access leaders

Organisations preparing launches should embed system value evidence from the outset rather than attempting to retrofit population data after approval. That means supplementing conventional cost-effectiveness models with analyses of avoided admissions, low-value care displacement and multi-condition populations. Pricing strategies must treat predictability of spend as a core element of negotiation. Health technology assessment bodies should expand requirements for productivity and societal effects where these influence real-world resource allocation. Investment in linked data infrastructure, with transparent governance for any AI-supported evidence processes, will further strengthen the credibility of submissions.

Looking ahead for health systems

The questions payers now pose centre on long-term sustainability and pathway redesign. Companies and health systems that treat system value evidence as the link between scientific findings and operational reality will be better placed to secure timely access while protecting overall budget impact. Continued attention to these dynamics will determine how effectively new technologies translate into measurable population benefit under tightening fiscal conditions.

Frequently asked questions

What is system value evidence?

It links clinical outcomes to population-level effects and capacity constraints, so payers can judge operational choices such as bed closures, admission avoidance and workforce reallocation.

Why does system value evidence matter for pricing?

Companies face difficult choices between delayed launches and lower returns, and system value evidence quantifies the trade-offs between headline price, expenditure predictability and the risk that new medicines bypass major markets.